Diurnal Group PLC Issue of Equity and Exercise of Options (3307H)

TIDMDNL

RNS Number : 3307H

Diurnal Group PLC

14 November 2018

14 November 2018

Diurnal Group plc

("Diurnal" or the "Company")

Exercise of Options

Issue of Equity

Diurnal Group plc (AIM: DNL), announces that, following the exercise of share options by a former consultant to the Company, an application has been made for 363,543 ordinary shares of 5 pence each in the Company ("New Ordinary Shares") to be admitted to trading on AIM.

The New Ordinary Shares will rank pari-passu with existing ordinary shares and it is expected that admission will occur at 8.00 a.m. on 19 November 2018.

Following admission of the New Ordinary Shares, the Company's issued ordinary share capital will consist of 61,700,066 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights in Diurnal following Admission will be 61,700,066.

The above figure of 61,700,066 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 
 For further information, please visit www.diurnal.co.uk or contact: 
 
                                                       [phone] 
 Diurnal Group plc                                      1000 
 Martin Whitaker, Chief Executive Officer 
 Richard Bungay, Chief Financial Officer 
 
 Panmure Gordon (UK) Limited (Nominated Adviser        [phone] 
  and Joint Broker)                                     2500 
 Corporate Finance: Freddy Crossley, Emma Earl 
 Corporate Broking: James Stearns 
 
                                                       [phone] 
 Cantor Fitzgerald Europe (Joint Broker)                7000 
 Corporate Finance: Phil Davies, Will Goode, 
  Michael Boot 
 Healthcare Equity Sales: Andrew Keith 
 
                                                       [phone] 
 FTI Consulting (Media and Investor Relations)          1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Notes to Editors

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

IOEBGBDBLGBBGIS

(END) Dow Jones Newswires

November 14, 2018 05:16 ET (10:16 GMT)